Default company panoramic image
Logo

DesignMedix

DesignMedix, Inc develops drugs to overcome drug resistance in multiple diseases, and has a malaria drug nearly ready for human trials.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Portland, OR, USA
  • Currency USD
  • Founded June 2008
  • Employees 5
  • Website designmedix.com

Company Summary

DesignMedix develops drugs to overcome drug resistance in multiple diseases that kill millions of people each year. Drug resistance is one of the top threats to human health. Leveraged by grants, most recently an award of $3 million from NIH, DesignMedix has efficiently used angel investment to develop a novel drug to cure malaria that is ready for human trials soon. Other projects address reversing drug resistance in bacterial diseases.

Team

  • Default avatar
    Lynnor B Stevenson
    CEO and Board Chair

    Lynnor Stevenson, PhD, has 30 yrs experience bioscience startups. CEO of 4 bio companies including Heska (HSKA), and member of 10 founding teams for companies, 6 of which had successful exits by IPO. She was the founding CEO and a long time member of the Board of Directors of Heska Corporation, a public animal health company that develops drugs, vaccines and diagnostics.

  • Default avatar
    Sandra L Shotwell
    President & COO

    Sandra Shotwell, PhD, has 20 yrs experience in technology commercialization and startups, including 3 yrs as Head of Licensing, NIH. Experience includes negotiating license and research partnerships with large pharmaceutical companies, and founding and serving as a board member for start-up companies. She also is a nationally-recognized authority on the role of intellectual property in the development of drugs for neglected diseases.

  • Default avatar
    David H Peyton
    CSO

    David Peyton, PhD., is co-inventor of DM technology. He has been working on medicinal chemistry of malaria for more than a decade and brings over two decades of organic, physical, and analytical chemistry experience. He is a Professor of Chemistry at PSU, where he has been since 1987.

  • Default avatar
    James Wilson
    Director

    James Wilson, M.S. is a senior executive with more than 20 years experience in providing clinical trial services to the biopharmaceutical industries. He joined Clinimetrics in 1989 and served as co-principal, growing the company entirely through retained earnings to more than 350 world-wide employees prior to being acquired by fortune 500
    company, Omnicare. He is an active angel investor.

  • Default avatar
    Erik Iverson
    Director

    Erik Iverson is EVP, Business Development at the Infectious Disease Research Institute (IDRI) Seattle, Wa, a global health research institute developing diagnostics, vaccines, and treatments for neglected diseases of poverty. Prior to joining IDRI, he was Associate General Counsel at the Bill & Melinda Gates Foundation where he led development and implementation of the Foundation’s Global Access policy through grants and strategic initiatives.

Advisors

  • Default avatar
    Ater, Wynne
    Lawyer
    Unconfirmed
    Default avatar
    KS & Co
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Oregon Angel Fund
    Unconfirmed
    Default avatar
    Private Angel Investors
    Unconfirmed
    Default avatar
    NW Technology Venturees
    Unconfirmed